Large-scale testing (Phase 3)Study completedNCT02787551
What this trial is testing
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Who this might be right for
Type 2 Diabetes Mellitus
Sanofi 514